Patent · US Active

Coronavirus vaccine

US12194089B2 · kind B2 · utility

0Cited by

32References

52Claims

0Family size

Assignee

CureVac SE · DE

Inventors

Susanne RAUCH · Tübingen, DE
Hans Wolfgang GROßE · Tübingen, DE
Benjamin PETSCH · Tübingen, DE

Key dates

Filing date	Feb 3, 2021
Grant date	Jan 14, 2025
Priority date	—
Expiry date	Mar 22, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2770/20034
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-COV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.